Quest Diagnostics (DGX) Tops Q4 EPS by 16c; Offers 2022 Guidance

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $3.33, $0.16 better than the analyst estimate of $3.17. Revenue for the quarter came in at $2.67 billion versus the consensus estimate of $2.66 billion.

GUIDANCE:

Quest Diagnostics sees FY2022 EPS of $8.65-$9.35, versus the consensus of $8.71. Quest Diagnostics sees FY2022 revenue of $9-9.5 billion, versus the consensus of $9.21 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
• RBC Capital Starts Tabcorp Holdings (TAH:AU) (TABCF) at Outperform
• Rubico to shift from semi-annual to quarterly financial reporting